source
- Bausch + Lomb appoints board chair Thomas Appio as interim CEO after Brent Saunders departsBausch + Lomb announced that board chair Thomas Appio will serve as interim chief executive, taking over immediately from Brent Saunders, who is leaving the role. Appio, who has held several leade…
- Novartis licenses Abogen’s mRNA CD19×CD3 engager in $575M upfront dealAbogen Biosciences saw its COVID vaccine miss the market, prompting questions about whether its mRNA platform could be leveraged for other therapies. Novartis agreed to pay $575 million up front f…